24 articles with Roche Group
Convelo Therapeutics Enters Into Collaboration and Option to Acquire Agreement With Genentech to Discover Novel Remyelinating Therapies
The collaboration will build on the remyelinating targets and proprietary screening platform developed by Convelo’s scientific founders Drs Paul Tesar and Drew Adams.
Clover Health Launches Clover Therapeutics, a New Research Subsidiary to Develop Treatment for Chronic Diseases
Newly inked research collaboration and license agreement with Genentech aims to better understand the genetics of ocular diseases
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu
The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years
Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris
Genentech, a member of the Roche Group, announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV).
Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study
Genentech, a member of the Roche Group, announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® for adults with proliferative lupus nephritis.
Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Approval Triggers Milestone Payment and Royalties on Worldwide Net Sales
Genentech announced that the Phase III BLOCKSTONE study, conducted by Shionogi & Co., Ltd., met its primary endpoint showing that people exposed to a household member with influenza and treated preventatively with XOFLUZA™ were significantly less likely to develop the disease compared to those treated with placebo.
Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies
Genentech, a member of the Roche Group, announced positive topline data from two Phase III multicenter studies evaluating Xolair® for the treatment of adults with chronic rhinosinusitis with nasal polyps who have not adequately responded to intranasal corticosteroids.
Start Codon Founded in Cambridge, UK, to Deliver Premier Life Science and Healthcare Business Acceleration Program
Start Codon, located in the heart of the Cambridge Cluster, aims to provide a much-needed world-class life science accelerator that offers significant funding and support to rapidly translate the most disruptive and innovative research into successful start-up companies.
FDA Approves Genentech’s Perjeta (pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
Genentech announced the FDA has approved Perjeta (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen).
Avastin was previously granted provisional approval in this setting under the FDA's accelerated approval program.
Ten Genentech medicines will be featured in over 75 abstracts, including 26 oral presentations, across eight blood diseases.
Genentech To Present New OCREVUS (Ocrelizumab) Efficacy & Safety Data In Relapsing And Primary Progressive Forms Of Multiple Sclerosis At ECTRIMS
Genentech announced today that new data on OCREVUS (ocrelizumab) in people with relapsing and primary progressive forms of multiple sclerosis (MS) will be presented during the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis.
Cancer Genetics Partners With Ventana Medical Systems, A Member Of The Roche Group To Ensure Market Access To Predictive Biomarker Test For New mmuno-Oncology (IO) Therapy For Advanced Bladder Cancer
Franz B. Humer, Former Chairman And CEO Of Roche Group, Appointed To Kite Pharma's Board Of Directors
Ventana Medical Systems, Inc. to Collaborate With Boehringer Ingelheim Corporation on the Development of Companion Diagnostic Tests
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Genentech Release: ACTEMRA Data Presented at American College of Rheumatology Annual Meeting on Rapid Response and Long-Term Efficacy in People with Rheumatoid Arthritis